PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1799171
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1799171
Perivascular Epithelioid Cell Tumors (PEComa)
Global Perivascular Epithelioid Cell Tumors (PEComa) Market to Reach US$69.7 Million by 2030
The global market for Perivascular Epithelioid Cell Tumors (PEComa) estimated at US$54.2 Million in the year 2024, is expected to reach US$69.7 Million by 2030, growing at a CAGR of 4.3% over the analysis period 2024-2030. PEComa Treatment, one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$41.4 Million by the end of the analysis period. Growth in the PEComa Diagnosis segment is estimated at 5.7% CAGR over the analysis period.
The U.S. Market is Estimated at US$14.2 Million While China is Forecast to Grow at 4.3% CAGR
The Perivascular Epithelioid Cell Tumors (PEComa) market in the U.S. is estimated at US$14.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$11.3 Million by the year 2030 trailing a CAGR of 4.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.8% and 3.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.
Global Perivascular Epithelioid Cell Tumors (PEComa) Market - Key Trends & Drivers Summarized
Why Are PEComas Gaining Significance in Oncologic and Rare Tumor Management?
Perivascular epithelioid cell tumors (PEComas) represent a rare group of mesenchymal tumors characterized by the co-expression of melanocytic and smooth muscle markers. Though histologically benign in most cases, some PEComas display malignant behavior, including local invasion, recurrence, and metastasis. These tumors can arise in various organs such as the uterus, lung, gastrointestinal tract, kidneys, liver, and soft tissues, making diagnosis and treatment a challenge across disciplines.
Their rarity and histopathological ambiguity have traditionally made PEComas a diagnostic dilemma. However, advances in immunohistochemistry and molecular profiling-particularly the identification of TSC1/TSC2 gene mutations and mTOR pathway activation-have significantly improved diagnostic accuracy and paved the way for targeted therapies. PEComas are now being recognized as part of a larger family of tumors associated with tuberous sclerosis complex (TSC), especially in younger individuals or those with syndromic features.
With rising awareness among oncologists and pathologists, PEComas are no longer misclassified as other smooth muscle or melanoma-like tumors. This trend is improving early identification, appropriate treatment planning, and long-term surveillance, particularly in tertiary cancer centers and sarcoma referral networks. Multidisciplinary tumor boards are now including PEComa-specific treatment algorithms that encompass surgery, molecular diagnostics, and systemic therapies.
How Are Targeted Therapies and Molecular Insights Reshaping PEComa Treatment?
The most transformative trend in PEComa treatment has been the shift toward molecularly targeted therapies, particularly those targeting the mammalian target of rapamycin (mTOR) signaling pathway. Mutations in TSC1 and TSC2, which are tumor suppressor genes, lead to constitutive activation of mTOR, making it a rational target for therapy. Drugs such as sirolimus, everolimus, and temsirolimus-originally developed as immunosuppressants or for renal cell carcinoma-are now repurposed as front-line or salvage therapies for advanced PEComas.
Clinical case reports and small-scale trials have demonstrated disease stabilization and partial responses with mTOR inhibitors in patients with metastatic or unresectable PEComas. These agents are often preferred over traditional chemotherapies, which have shown limited efficacy due to the tumor’s indolent growth and low mitotic index. Ongoing trials are exploring the role of dual mTORC1/mTORC2 inhibitors and combinations with VEGF or immune checkpoint inhibitors to address resistance and expand therapeutic options.
Immunohistochemistry using HMB-45, Melan-A, SMA, and desmin, combined with next-generation sequencing (NGS), is enabling precise tumor classification and therapy guidance. Liquid biopsy and circulating tumor DNA (ctDNA) analysis may emerge as non-invasive tools for monitoring treatment response and detecting minimal residual disease. These molecular approaches are shifting the paradigm from generic oncologic treatment to personalized rare tumor care.
Which Care Settings and Regions Are Influencing PEComa Management Patterns?
Due to their rarity, PEComas are predominantly managed in academic medical centers, sarcoma specialty clinics, and cancer referral hospitals equipped with advanced diagnostics and rare tumor boards. Most cases are initially suspected during imaging for unrelated complaints or following resection of masses presumed to be fibromas, lipomas, or uterine leiomyomas. Delayed diagnosis is common, but increasing use of MRI, PET-CT, and image-guided biopsies is improving detection rates.
Surgical resection remains the cornerstone of curative treatment in localized disease. However, due to potential malignant transformation, recurrence risk, and multifocality (especially in TSC patients), long-term surveillance is essential. In metastatic cases, systemic mTOR inhibitors are typically initiated at comprehensive cancer centers with access to genomic profiling. Radiotherapy is reserved for select cases, particularly where complete surgical resection is not feasible.
North America and Europe lead in terms of published case series, access to mTOR inhibitors, and diagnostic molecular tools. Asia-Pacific is seeing increasing awareness and clinical reporting, especially from Japan and South Korea. Latin America and Africa have limited case documentation, but international tumor registries and rare disease networks are helping bridge gaps in care delivery, diagnosis, and treatment standardization.
What Is Driving Growth in the Global PEComa Treatment Market?
The growth in the global PEComa market is driven by improved disease recognition, the emergence of mTOR inhibitors as targeted therapies, the expanding application of genomic diagnostics, and the development of specialized care networks for rare cancers. As more clinicians become aware of the molecular underpinnings and distinct treatment needs of PEComa, earlier diagnosis and tailored therapy are becoming standard practice.
Regulatory approvals and off-label use of mTOR inhibitors have given physicians effective options for managing aggressive or unresectable PEComas. Pharmaceutical interest in repurposing cancer drugs for rare tumors is increasing, supported by orphan drug designations, fast-track pathways, and growing patient advocacy. Furthermore, improvements in rare tumor surveillance registries, NGS-based diagnostic algorithms, and multidisciplinary care models are supporting growth in both diagnosis and treatment.
As molecular medicine becomes central to oncology, PEComa care exemplifies the potential for personalized therapy in ultra-rare cancers. The continued collaboration between clinicians, researchers, and biotech developers will be crucial in expanding access, reducing misdiagnosis, and improving long-term outcomes for this enigmatic tumor family.
SCOPE OF STUDY:
The report analyzes the Perivascular Epithelioid Cell Tumors (PEComa) market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Type (PEComa Treatment, PEComa Diagnosis); End-Use (Hospitals End-Use, Diagnostic Centers End-Use, Other End-Uses)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Select Competitors (Total 41 Featured) -
- Aadi Bioscience
- AstraZeneca
- Bayer
- Celgene (Bristol Myers Squibb)
- Daiichi Sankyo
- Eisai Co., Ltd.
- Exelixis
- Ipsen
- Loxo Oncology (Eli Lilly)
- Merck & Co.
- Novartis
- Pfizer
- Roche
- Sanofi
- Seagen
- Sun Pharma
- Taiho Pharmaceutical
- Takeda
- Turning Point Therapeutics
- Bristol Myers Squibb
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Tariff Impact on Global Supply Chain Patterns
- Perivascular Epithelioid Cell Tumors (PEComa) - Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Rising Incidence of Rare Soft Tissue Tumors Throws the Spotlight on PEComa Diagnosis and Therapy
- Increased Use of Immunohistochemical and Molecular Profiling Drives Accurate PEComa Identification
- Expansion of Targeted Oncology Therapies Strengthens Business Case for PEComa-Specific Treatment Development
- FDA Approvals for mTOR Inhibitors Propel Market for Targeted PEComa Management
- Growth in Rare Cancer Registries Enhances Data Availability and Clinical Insights on PEComa
- Adoption of Next-Generation Sequencing in Rare Tumor Diagnosis Fuels Personalized Therapy Development
- Academic Research Consortia Drive Multi-Institutional Trials on PEComa Treatment Efficacy
- Rising Awareness Among Oncologists Expands Early Diagnosis and Intervention Rates
- Global Clinical Trial Activity for PEComa Therapeutics Expands Addressable Market for Biopharma Firms
- Advances in Immuno-Oncology Support Development of Novel Approaches for PEComa
- Integration of AI in Tumor Classification Enhances Diagnostic Accuracy for Rare Malignancies
- Growing Patient Advocacy Networks Drive Research Funding and Diagnostic Tool Accessibility
- Surge in Orphan Drug Designation Programs Spurs Innovation in PEComa Drug Pipelines
- Standardization of Histopathologic Criteria Strengthens Diagnostic Consistency Across Centers
- Improved Access to PET-CT and MRI Imaging Enhances Detection of PEComa Metastasis
- Biomarker-Driven Clinical Decision Support Tools Enable Tailored PEComa Treatment Regimens
- Collaborative Rare Tumor Repositories Promote Data Sharing and Therapeutic Advancements
- Regulatory Incentives for Orphan Oncology Drugs Accelerate Market Entry for PEComa Therapies
- Emergence of Real-World Evidence Platforms Enhances Treatment Evaluation in Low-Incidence Cancers
- Precision Oncology Platforms Expand Companion Diagnostic Development for PEComa Patient Stratification
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Perivascular Epithelioid Cell Tumors (PEComa) Market Analysis of Annual Sales in US$ for Years 2014 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
- TABLE 3: World 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
- TABLE 4: World Recent Past, Current & Future Analysis for PEComa Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
- TABLE 5: World 6-Year Perspective for PEComa Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 6: World Recent Past, Current & Future Analysis for PEComa Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
- TABLE 7: World 6-Year Perspective for PEComa Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
- TABLE 9: World 6-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 10: World Recent Past, Current & Future Analysis for Diagnostic Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
- TABLE 11: World 6-Year Perspective for Diagnostic Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 12: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
- TABLE 13: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
III. MARKET ANALYSIS
- UNITED STATES
- Perivascular Epithelioid Cell Tumors (PEComa) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 14: USA Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by Type - PEComa Treatment and PEComa Diagnosis - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 15: USA 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by Type - Percentage Breakdown of Value Sales for PEComa Treatment and PEComa Diagnosis for the Years 2025 & 2030
- TABLE 16: USA Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 17: USA 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2025 & 2030
- CANADA
- TABLE 18: Canada Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by Type - PEComa Treatment and PEComa Diagnosis - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 19: Canada 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by Type - Percentage Breakdown of Value Sales for PEComa Treatment and PEComa Diagnosis for the Years 2025 & 2030
- TABLE 20: Canada Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 21: Canada 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2025 & 2030
- JAPAN
- Perivascular Epithelioid Cell Tumors (PEComa) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 22: Japan Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by Type - PEComa Treatment and PEComa Diagnosis - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 23: Japan 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by Type - Percentage Breakdown of Value Sales for PEComa Treatment and PEComa Diagnosis for the Years 2025 & 2030
- TABLE 24: Japan Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 25: Japan 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2025 & 2030
- CHINA
- Perivascular Epithelioid Cell Tumors (PEComa) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 26: China Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by Type - PEComa Treatment and PEComa Diagnosis - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 27: China 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by Type - Percentage Breakdown of Value Sales for PEComa Treatment and PEComa Diagnosis for the Years 2025 & 2030
- TABLE 28: China Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 29: China 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2025 & 2030
- EUROPE
- Perivascular Epithelioid Cell Tumors (PEComa) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 30: Europe Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
- TABLE 31: Europe 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
- TABLE 32: Europe Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by Type - PEComa Treatment and PEComa Diagnosis - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 33: Europe 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by Type - Percentage Breakdown of Value Sales for PEComa Treatment and PEComa Diagnosis for the Years 2025 & 2030
- TABLE 34: Europe Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 35: Europe 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2025 & 2030
- FRANCE
- Perivascular Epithelioid Cell Tumors (PEComa) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 36: France Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by Type - PEComa Treatment and PEComa Diagnosis - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 37: France 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by Type - Percentage Breakdown of Value Sales for PEComa Treatment and PEComa Diagnosis for the Years 2025 & 2030
- TABLE 38: France Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 39: France 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2025 & 2030
- GERMANY
- Perivascular Epithelioid Cell Tumors (PEComa) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 40: Germany Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by Type - PEComa Treatment and PEComa Diagnosis - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 41: Germany 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by Type - Percentage Breakdown of Value Sales for PEComa Treatment and PEComa Diagnosis for the Years 2025 & 2030
- TABLE 42: Germany Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 43: Germany 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2025 & 2030
- ITALY
- TABLE 44: Italy Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by Type - PEComa Treatment and PEComa Diagnosis - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 45: Italy 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by Type - Percentage Breakdown of Value Sales for PEComa Treatment and PEComa Diagnosis for the Years 2025 & 2030
- TABLE 46: Italy Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 47: Italy 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2025 & 2030
- UNITED KINGDOM
- Perivascular Epithelioid Cell Tumors (PEComa) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 48: UK Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by Type - PEComa Treatment and PEComa Diagnosis - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 49: UK 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by Type - Percentage Breakdown of Value Sales for PEComa Treatment and PEComa Diagnosis for the Years 2025 & 2030
- TABLE 50: UK Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 51: UK 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2025 & 2030
- REST OF EUROPE
- TABLE 52: Rest of Europe Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by Type - PEComa Treatment and PEComa Diagnosis - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 53: Rest of Europe 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by Type - Percentage Breakdown of Value Sales for PEComa Treatment and PEComa Diagnosis for the Years 2025 & 2030
- TABLE 54: Rest of Europe Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 55: Rest of Europe 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2025 & 2030
- ASIA-PACIFIC
- Perivascular Epithelioid Cell Tumors (PEComa) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by Type - PEComa Treatment and PEComa Diagnosis - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 57: Asia-Pacific 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by Type - Percentage Breakdown of Value Sales for PEComa Treatment and PEComa Diagnosis for the Years 2025 & 2030
- TABLE 58: Asia-Pacific Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 59: Asia-Pacific 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2025 & 2030
- REST OF WORLD
- TABLE 60: Rest of World Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by Type - PEComa Treatment and PEComa Diagnosis - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 61: Rest of World 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by Type - Percentage Breakdown of Value Sales for PEComa Treatment and PEComa Diagnosis for the Years 2025 & 2030
- TABLE 62: Rest of World Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 63: Rest of World 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2025 & 2030
IV. COMPETITION
